US OptionsDetailed Quotes

BMEA250117P5000

Watchlist

0.89
-0.11-11.00%

15min DelayClose Jan 8 16:00 ET

1.00High0.85Low

Biomea Fusion Stock Discussion

我要向钱看

Jan 7 08:21

NEW PRECLINICAL DATA

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...

我要向钱看

Jan 7 08:09

UPDATES

$Biomea Fusion (BMEA.US)$ REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Confer...

Moo Top

Jan 7 08:05

Pump and Dump..

$Biomea Fusion (BMEA.US)$ $Biomea Fusion (BMEA.US)$

Trytosaveabit

Jan 7 08:05

Update

$Biomea Fusion (BMEA.US)$ Reuters· 3 mins ago
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Thanks @Jaguar8 For spotting since for some reason they say no more posts???

我要向钱看

Jan 6 06:07

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

我要向钱看

Dec 20, 2024 18:28

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events

Kraks

Dec 18, 2024 09:09

Analysts Vs reality

$Biomea Fusion (BMEA.US)$ is -without doubts- burning money at a super high speed.
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?

The Only Way is Up

Dec 18, 2024 03:58

Can we expect it to go lower to 3.0?

$Biomea Fusion (BMEA.US)$

SteadyBoomBeepBeep

Dec 18, 2024 01:15

$Biomea Fusion (BMEA.US)$ expecting offering for ATM after the next catalyst on March 2025. Monthly cash burning up to 10mil and should deplete by April / May 2025.

Jaguar8

Dec 17, 2024 16:55

🟡Watchlist WEDNESDAY December 18,2024

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...

The CES showcase is here! Where's the next breakthrough in AI?

No comment yet